Inhibrx Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 172
- Market Cap
- $205.4M
- Website
- http://inhibrx.com
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 410
- Registration Number
- NCT06295731
- Locations
- 🇺🇸
UC Davis, Sacramento, California, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇧🇪University Hospital Brussels, Jette, Belgium
Study of INBRX-109 in Conventional Chondrosarcoma
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 201
- Registration Number
- NCT04950075
- Locations
- 🇺🇸
Precision NextGen Oncology & Research Center, Beverly Hills, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Oklahoma - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Conditions
- Solid TumorRenal Cell CarcinomaHead and Neck CancerUrothelial CarcinomaMelanomaNon-Small Cell Lung CancerGastric Cancer
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 333
- Registration Number
- NCT04198766
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Winship Cancer Institute - Emory University, Atlanta, Georgia, United States
🇺🇸Vanderbilt University School of Medicine, Nashville, Tennessee, United States
Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
- Conditions
- Alpha-1 Antitrypsin DeficiencyAATD
- Interventions
- Drug: INBRX-101/rhAAT-Fc
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 31
- Registration Number
- NCT03815396
- Locations
- 🇺🇸
UC Davis School of Medicine, Sacramento, California, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸University of Miami, Miami, Florida, United States
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
- Conditions
- Head and Neck Squamous Cell CarcinomaNon-small Cell Lung CancerMelanomaGastric AdenocarcinomaMetastatic Solid TumorsRenal Cell CarcinomaNasopharyngeal CarcinomaEsophageal AdenocarcinomaOropharyngeal Carcinoma
- Interventions
- Drug: INBRX-105 - PDL1x41BB antibody
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 160
- Registration Number
- NCT03809624
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Conditions
- Colorectal AdenocarcinomaEwing Sarcoma
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 321
- Registration Number
- NCT03715933
- Locations
- 🇺🇸
Precision NextGen Oncology and Research, Beverly Hills, California, United States
🇺🇸University of California, San Francisco (UCSF), San Francisco, California, United States
🇺🇸Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States